GLS and ovarian carcinoma: Hudson and colleagues also identified a negative correlation between expression of GLS and prognostic outcomes (i.e., progression-free and overall survival) in ovarian cancer patients, and showed that inhibition of GLS activity by an inhibitor sensitized the ovarian cancer cells to cisplatin treatment [40].